Novartis boosts outlook, announces $2.1B Endocyte deal
The Swiss healthcare company is paying 24 dollars per share in cash for Endocyte.
Thursday, October 18, 2018
Novartis boosts outlook, announces $2.1B Endocyte deal
Novartis boosts outlook, announces $2.1B Endocyte deal
The Swiss healthcare company is paying 24 dollars per share in cash for Endocyte.
Related Posts:
0 comments:
Post a Comment